STOCKHOLM, Oct. 22, 2020 /PRNewswire/ -- IRRAS AB, a
commercial-stage medical technology company with a comprehensive
portfolio of innovative products for neurocritical care, today
announced important commercial milestones from the launch of its
IRRAflow system in Germany.
The company generated its initial revenue in Germany and also completed the first German
patient since launching the most recent version of
IRRAflow.
Initial Evaluation Agreement Signed, First Revenue
Generated
The latest generation of IRRAflow was launched in
Europe in the first quarter of
this year after securing the product's CE Mark certification in
December 2019. The covid-19 pandemic
slowed the launch of this IRRAflow system, but the IRRAS
team in Germany has been able to
secure physician support for product evaluations and train hospital
staff remotely in recent months.
The first agreement to evaluate IRRAflow has been signed
by BG Klinikum Bergmannstrost in Halle, Germany, which placed an order for
IRRAflow disposable kits to support an evaluation by Dr.
med. Felix Goehre. This facility did
not have experience with IRRAflow during its earlier German
commercial availability and will be a new customer for IRRAS. The
evaluation will begin later in the 4th quarter after
product training has been completed for the nursing staff.
"The reintroduction of IRRAflow into the German market
represents a major step forward for IRRAS," said Coenraad Tamse, Vice President, International
Sales, of IRRAS. "Germany is the
largest market for neurosurgery in Europe, and we are pleased with extensive
growth opportunities that we have seen from German customers."
First Patient Treatment
In addition, the first patient in Germany has been treated using the latest
generation IRRAflow system. Dr. Jan
Leppert at Universitätsklinikum Schleswig-Holstein (UKSH),
located in Lübeck, treated a ventricular hemorrhage with
IRRAflow after multiple traditional drainage catheters
became blocked. Dr. Leppert and the hospital in Lübeck had
previously treated patients in 2017 and 2018 when the earlier
version of IRRAflow was available in Germany.
"The fact that the UKSH in Lübeck has resumed patient treatments
using the latest IRRAflow version is a confirmation of the patient
benefits that the system offers," added Mr. Tamse. "Beyond
Lübeck, other previous IRRAS customers have confirmed their
interest in resuming IRRAflow treatments after refresher training
is completed."
About IRRAS
IRRAS is a global medical care company focused on delivering
innovative medical solutions to improve the lives of critically ill
patients. IRRAS designs, develops, and commercializes neurocritical
care products that transform patient outcomes and decrease the
overall cost of care by addressing complications associated with
current treatment methodologies. IRRAS markets and sells its
comprehensive, innovative IRRAflow and Hummingbird ICP
Monitoring product lines to hospitals worldwide through its direct
sales organization in the United
States and select European countries as well as an
international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).
For more information, please contact:
USA
Kleanthis G. Xanthopoulos, Ph.D.
CEO
ir@irras.com
Europe
Sabina Berlin
CFO
+46 73 951 95 02
sabina.berlin@irras.com
The information was released for public disclosure, through
the agency of the contact person above, on October 22, 2020 at 11:30
(CET).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/irras-announces-key-irraflow-commercial-milestones-in-germany,c3220932
View original
content:http://www.prnewswire.com/news-releases/irras-announces-key-irraflow-commercial-milestones-in-germany-301157809.html
SOURCE IRRAS